PMID- 31685833
OWN - NLM
STAT- MEDLINE
DCOM- 20201103
LR  - 20221207
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 9
IP  - 1
DP  - 2019 Nov 4
TI  - Human papillomavirus and human telomerase RNA component gene in cervical cancer 
      progression.
PG  - 15926
LID - 10.1038/s41598-019-52195-5 [doi]
LID - 15926
AB  - This study aimed to examine hTERC gene in different grades of cervical 
      intraepithelial neoplasia (CIN) and cervical cancer, and the association between 
      hTERC and high risk-human papillomavirus (HR-HPV) infection. Patients who 
      underwent cervical cancer screening at the Second Affiliated Hospital of Kunming 
      Medical University between October 2010 and December 2011 were enrolled. All 
      patients underwent liquid-based cytology test and hybrid capture 2 (HC2) for HPV 
      detection. hTERC was examined using fluorescence in situ hybridization (FISH). 
      Cervical colposcopy biopsy was performed if any of the three results was 
      positive. HC2, FISH, and pathology were compared. A total of 1200 women underwent 
      screening, 150 patients underwent cervical biopsy: 32 in the normal group, 38 in 
      the CIN1 group, 66 in the CIN2/3 group, and 14 in the invasive cervical cancer 
      group. More patients had HR-HPV infection in the CIN2/3 group and ICC group 
      compared with the CIN1 group. hTERC increased with increasing histological 
      dysplasia. There was significant difference in hTERC positive rate between each 
      of the three groups. More patients with hTERC gene amplification were observed in 
      the positive HR-HPV group than in the HR-HPV negative group. In conclusion, hTERC 
      is a potential marker for precancerous cervical cancer lesions. hTERC might be 
      correlated with HR-HPV infection in cervical diseases.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Reproductive, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Fan, Pianping
AU  - Fan P
AD  - Department of Gynecology, LinFen Central Hospital of Shanxi Province, LinFen, 
      Shanxi, 041000, P.R. China.
FAU - Yang, Yingying
AU  - Yang Y
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Xu, Changjun
AU  - Xu C
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Huang, Yajuan
AU  - Huang Y
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Li, Daizhu
AU  - Li D
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Qing, Qing
AU  - Qing Q
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China.
FAU - Sun, Chunyi
AU  - Sun C
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China. 787413869@qq.com.
FAU - Zhou, Honglin
AU  - Zhou H
AD  - Department of Gynecology, the Second Affiliated Hospital of Kunming Medical 
      University, Kunming, Yunnan, 650101, P.R. China. km20150515@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20191104
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (telomerase RNA)
RN  - 63231-63-0 (RNA)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Nucleic Acid Amplification Techniques
MH  - Papillomaviridae/*genetics
MH  - Papillomavirus Infections/genetics/pathology
MH  - RNA/genetics/*metabolism
MH  - Telomerase/genetics/*metabolism
MH  - Uterine Cervical Neoplasms/genetics/*pathology/virology
MH  - Uterine Cervical Dysplasia/complications/pathology/virology
PMC - PMC6828729
COIS- The authors declare no competing interests.
EDAT- 2019/11/07 06:00
MHDA- 2020/11/04 06:00
PMCR- 2019/11/04
CRDT- 2019/11/06 06:00
PHST- 2019/03/11 00:00 [received]
PHST- 2019/09/24 00:00 [accepted]
PHST- 2019/11/06 06:00 [entrez]
PHST- 2019/11/07 06:00 [pubmed]
PHST- 2020/11/04 06:00 [medline]
PHST- 2019/11/04 00:00 [pmc-release]
AID - 10.1038/s41598-019-52195-5 [pii]
AID - 52195 [pii]
AID - 10.1038/s41598-019-52195-5 [doi]
PST - epublish
SO  - Sci Rep. 2019 Nov 4;9(1):15926. doi: 10.1038/s41598-019-52195-5.